Minimally Invasive Surgical Epilepsy Trial for Temporal Lobe Epilepsy
NCT05019404 · Status: UNKNOWN · Phase: NA · Type: INTERVENTIONAL · Enrollment: 120
Last updated 2022-12-30
Summary
Temporal lobe epilepsy (TLE) is a chronically neurological disease characterized by progressive seizures. TLE is the most frequent subtype of refractory focal epilepsy in adults. Epilepsy surgery has proven to be very efficient in TLE and superior to medical therapy in two randomized controlled trials. According to the previous experience, the investigators use functional anterior temporal lobectomy (FATL) via minicraniotomy for TLE. To date, this minimally invasive open surgery has been not reported. The investigators here present a protocol of a prospective trail which for the first time evaluates the outcomes of this new surgical therapy for TLE.
Conditions
- Temporal Lobe Epilepsy
- Open Surgery
- Minimally Invasive Surgery
Interventions
- PROCEDURE
-
Functional anterior temporal lobectomy (FATL)
Patients are placed in the supine position with the head contralaterally rotated 30°. The 3D model of incision and bone flap is printed prior to surgery by the slicer software based on the MRI data. Slightly curve incision with the length of about 6 cm in the temporal region is marked according to the 3D model. Temporal craniotomy via small bone window with the diameter of about 3 cm is performed. From the temporal pole along T1 about 5 cm posteriorly, temporal horn is opened by dissecting the middle temporal gyrus. The head of temporal horn is exposed. The amygdala is resected. Then, the parahippocampal gyrus and hippocampus are en bloc resected. The lateral temporal lobotomy is easy due to large view following the removal of mesial structures. The lateral posterior temporal lobotomy is no more than 5 cm from the temporal pole.
- PROCEDURE
-
Anterior temporal lobectomy (ATL)
Patients are placed in the supine position with the head contralaterally rotated 30°. Large frontotemporal craniotomy is performed. Question mark-shaped incision with the length of 20- 25 cm in the frontotemporal region is marked. The size of the bone flap is approximately 5×7 cm for the exposure of lateral temporal lobe. ATL consists of en bloc resection of the anterior 5 cm of lateral temporal lobe, followed by the removal of mesial structures including the amygdala, parahippocampal gyrus, and hippocampus.
Sponsors & Collaborators
-
First Affiliated Hospital Xi'an Jiaotong University
lead OTHER
Principal Investigators
-
Hua Zhang, PhD · First Affiliated Hospital Xi'an Jiaotong University
Study Design
- Allocation
- RANDOMIZED
- Purpose
- TREATMENT
- Masking
- SINGLE
- Model
- PARALLEL
Eligibility
- Min Age
- 18 Years
- Max Age
- 60 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2023-04-25
- Primary Completion
- 2024-09-01
- Completion
- 2025-09-01
Countries
- China
Study Locations
More Related Trials
-
Post-market Study of AMPA Receptor Antagonists for Epilepsy Patients in Hong Kong
NCT03457961 ·Status: UNKNOWN
-
A Study of GWP42006 in People With Focal Seizures - Part A
NCT02369471 ·Status: COMPLETED ·Phase: PHASE2
-
Preoperative Speech Rehabilitation in Drug-Resistant Temporal Epilepsy: A Case Study
NCT05325047 ·Status: COMPLETED ·Phase: NA
-
Study to Assess Intracerebroventricular (ICV) Delivery of CT-010 in Subjects With Focal Seizures, With Temporal Lobe Onset With or Without Secondary Generalization
NCT04153175 ·Status: TERMINATED ·Phase: PHASE2
-
Study of Specimens Obtained During Epilepsy Surgery
NCT00025714 ·Status: COMPLETED
-
A Study to Evaluate the Safety, Tolerability, and Efficacy of CB03-154 in Adult Patients With Focal Epilepsy
NCT06612775 ·Status: NOT_YET_RECRUITING ·Phase: PHASE2
-
Clinical Efficacy and Safety of Perampanel Monotherapy in the Treatment of Children With Focal Epilepsy
NCT05497193 ·Status: UNKNOWN
-
Genetic and Electrophysiologic Study in Focal Drug-resistant Epilepsies
NCT02890641 ·Status: RECRUITING
-
An Open-Label Extension Study of the Effectiveness and Safety of the Investigational Compound RWJ-333369 in Patients With Epilepsy
NCT00210522 ·Status: COMPLETED ·Phase: PHASE2
-
Emotion/Behavior Problems, Neuropsychological Functioning, and Parental Adjustment in Children With Epilepsy
NCT00550940 ·Status: COMPLETED
-
A Study to Investigate Dosage, Effectiveness, and Safety of Perampanel When Used as First Add-on Therapy in Participants >=12 Years With Partial Onset Seizures With or Without Secondary Generalization or With Primary Generalized Tonic-Clonic Seizures Associated With Idiopathic Generalized Epilepsy
NCT04252846 ·Status: COMPLETED
-
An Open-Label Extension Study to Evaluate the Safety and Effectiveness of RWJ 333369 in Patients With Epilepsy
NCT00210652 ·Status: COMPLETED ·Phase: PHASE2
-
Exploratory Study of UX-GIP001 Cell Therapy in Adult Patients With Drug-Resistant Unilateral Mesial Temporal Lobe Epilepsy (MTLE)
NCT07244328 ·Status: RECRUITING ·Phase: EARLY_PHASE1
-
Seizure Prophylaxis in Patients With Glioma or Brain Metastasis
NCT03436433 ·Status: TERMINATED ·Phase: PHASE2
-
A Dose Ranging Pilot Study for Intracerebroventricular (ICV) Delivery of Valproate in Subjects With Temporal Seizures
NCT02899611 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
Efficacy of Omega-3 as Adjunctive Therapy for Medically Intractable Epilepsy: A Prospective Open-label Pilot Study
NCT02899741 ·Status: UNKNOWN ·Phase: PHASE2
-
A Study of Lu AG06466 in Participants With Treatment Resistant Focal Epilepsy
NCT05081518 ·Status: TERMINATED ·Phase: PHASE1
-
A Phase 1/2 Study of NRTX-1001 Neuronal Cell Therapy in Drug-Resistant Bilateral Mesial Temporal Lobe Epilepsy (MTLE)
NCT06422923 ·Status: RECRUITING ·Phase: PHASE1/PHASE2
-
A Study of the Safety of Topiramate Given in Combination With Other Medications in Adults and Children With Seizures
NCT00297349 ·Status: COMPLETED
-
Prospective Open-label Evaluation of Cenobamate Adjunctive Treatment of Adults With Refractory Focal Epilepsy
NCT04879433 ·Status: UNKNOWN
-
Study of NRTX-1001 Neural Cell Therapy in Drug-Resistant Unilateral Mesial Temporal Lobe Epilepsy (EPIC (EPIlepsy Cell Therapy))
NCT05135091 ·Status: RECRUITING ·Phase: PHASE3
-
Safety and Efficacy Study of Cenobamate in Pediatric Subjects 2-17 Years of Age With Partial-onset (Focal) Seizures
NCT05067634 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE3
-
Topiramate Treatment for Patients With Epilepsy and Learning Disability : A Prospective Observational Study
NCT00956696 ·Status: UNKNOWN
-
A Study of GWP42006 in People With Focal Seizures - Part B
NCT02365610 ·Status: COMPLETED ·Phase: PHASE2
-
Sleep Intervention for Pediatric Epilepsy
NCT02514291 ·Status: COMPLETED ·Phase: NA